● The recommended starting dosage of Wikijet for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose. The maximum recommended dosage is 15 mg once weekly in adults & 10 mg once weekly in pediatric patients. Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.

● Recommended maintenance dosage for weight reduction and long-term maintenance is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly & for obstructive sleep apnea the recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly. Wikijet is administered once weekly, on the same day `each week, at any time of the day, with or without meals. Wikijet is to be injected subcutaneously in the abdomen, thigh or in upper arm. The day of weekly administration can be changed, if necessary, as long as the time between two doses is at least 3 days (72 hours).

Tirzepatide is contraindicated in patients with known hypersensitivity to Tirzepatide or to any of the components. Also contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. Hypersensitivity Reactions: Hypersensitivity reactions have been reported. Discontinue Tirzepatide if suspected. Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Severe Gastrointestinal Disease: Use of tirzepatide may be associated with gastrointestinal adverse reactions, sometimes severe. Tirzepatide has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients. Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Patients with a history of diabetic retinopathy should be monitored. Risk of Thyroid C-cell Tumors.

Sometimes hypoglycemia can occur when used with sulfonylurea. The most frequent adverse reactions are gastrointestinal disorder, nausea, diarrhea, vomiting, abdominal pain and constipation. Beside these injection site reactions may occur.

Oral Medications: Tirzepatide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of other oral medications.

Pregnancy: Tirzepatide is contraindicated during pregnancy. If a patient wishes to become pregnant, Tirzepatide should be discontinued at least 1 month before a planned pregnancy due to the long half-life of Tirzepatide. Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Lactation: There are no data on the presence of Tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use: Safety and effectiveness of Tirzepatide have not been established in pediatric patients. Tirzepatide is not recommended for use in patients younger than 18 years.

Hepatic Impairment: No dose adjustment of Tirzepatide is recommended for patients with hepatic impairment.

Renal Impairment: No dose adjustment of Tirzepatide is recommended for patients with renal impairment.

Wikijet 2.5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 2.5 mg/0.5 ml injection.

Wikijet 5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 5 mg/0.5 ml injection.

Wikijet 7.5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 7.5 mg/0.5 ml injection.

Wikijet 10 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 10 mg/0.5 ml injection.

Wikijet 12.5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 12.5 mg/0.5 ml injection.

Wikijet 15 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 15 mg/0.5 ml injection.